NCT06983704CompletedEarly phase 1
Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma
Evaluation of Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma
Source: ClinicalTrials.gov · Last updated 21 May 2025
Brief summary (registry, in English)
To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 14 May 2025
- Start date
- 9 Feb 2024
- Primary completion date
- 8 Feb 2025
- Lead sponsor
- Benha University
- Diseases
- Glaucoma
- NCT number
- NCT06983704
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 50
- From 9 Feb 2024 to the primary completion date, 8 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- age \>12 years, eyes with no light perception, and those with prior cyclodestructive procedures.
Who the study is looking for
- children under 12 years with previous AGV implantation for primary congenital glaucoma
Age in the registry: - to 12 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Azhar University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.